The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Malyavin A.G.

Russian University of Medicine (Evdokimov Moscow State University of Medicine and Dentistry)

Chumovatov N.V.

Central Tuberculosis Research Institute

Chernyh N.A.

Central Tuberculosis Research Institute

Tobacco smoking as a factor in the development of COPD and pulmonary tuberculosis

Authors:

Malyavin A.G., Chumovatov N.V., Chernyh N.A.

More about the authors

Journal: Journal of Respiratory Medicine. 2025;1(2): 45‑50

Read: 657 times


To cite this article:

Malyavin AG, Chumovatov NV, Chernyh NA. Tobacco smoking as a factor in the development of COPD and pulmonary tuberculosis. Journal of Respiratory Medicine. 2025;1(2):45‑50. (In Russ.)
https://doi.org/10.17116/respmed2025102145

Recommended articles:
Issues of morphological diagnosis and pathogenesis of tube­rculosis. Russian Journal of Archive of Pathology. 2024;(5):81-93
Features of como­rbidity pathology in young people. Russian Journal of Preventive Medi­cine. 2024;(11):63-69
Surgical treatment of pulmonary tube­rculosis in children and adolescents. Piro­gov Russian Journal of Surgery. 2025;(3):16-23
Lung tube­rculosis and mali­gnant neoplasms: the current state of the problem. Russian Journal of Preventive Medi­cine. 2025;(3):122-127

References:

  1. Agustí A, Celli B, Criner G, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han M, Martinez F, Montes de Oca M, Mortimer K, Papi A, Pavord I, Roche N, Salvi S, Sin D, Singh D, Stockley R, López Varela M, Wedzicha J, Vogelmeier C. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. European Respiratory Journal. 2023;61(4):230-239.  https://doi.org/10.1183/13993003.00239-2023
  2. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Accessed January 18, 2025. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
  3. Zhao J, Li M, Chen J, Wu X, Ning Q, Zhao J, Xu Y, Xie J, Yu J. Smoking status and gene susceptibility play important roles in the development of chronic obstructive pulmonary disease and lung function decline: A population-based prospective study. Medicine. 2017;96(25):72-83.  https://doi.org/10.1097/MD.0000000000007283
  4. Khosa C, Bhatt N, Massango I, Azam K, Saathoff E, Bakuli A, Riess F, Ivanova O, Hoelscher M, Rachow A. Development of chronic lung impairment in Mozambican TB patients and associated risks. BMC Pulmonary Medicine. 2020;20(1):127.  https://doi.org/10.1186/s12890-020-1167-1
  5. Meghji J, Lesosky M, Joekes E, Banda P, Rylance J, Gordon S, Jacob J, Zonderland H, MacPherson P, Corbett EL, Mortimer K, Squire SB. Patient outcomes associated with post-tuberculosis lung damage in Malawi: A prospective cohort study. Thorax. 2020;75(3):269-278.  https://doi.org/10.1136/thoraxjnl-2019-213808
  6. Leung JM, Chen V, Hollander Z, Dai D, Tebbutt SJ, Aaron SD, Vandemheen KL, Rennard SI, FitzGerald JM, Woodruff PG, Lazarus SC, Connett JE, Coxson HO, Miller B, Borchers C, McManus BM, Ng RT, Sin DD. COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS ONE. 2016;11(8):e0161129. https://doi.org/10.1371/journal.pone.0161129
  7. Alowiwi H, Watson S, Jetmalani K, Thamrin C, Johns DP, Walters EH, King GG. Relationship between concavity of the flow-volume loop and small airway measures in smokers with normal spirometry. BMC Pulmonary Medicine. 2022;22(1):211.  https://doi.org/10.1186/s12890-022-01998-w
  8. Aisanov ZR, Avdeev SN, Arkhipov VV, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul’monologiya. 2017;27(1):13-20. (In Russ.). https://doi.org/10.18093/0869-0189-2017-27-1-13-20
  9. Bourzac K. Infectious disease: Beating the big three. Nature. 2014;507 (7490):4-7.  https://doi.org/10.1038/507s4a
  10. Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018;23(10):893-900.  https://doi.org/10.1111/resp.13346
  11. Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Safety. 2015;38(3):253-269.  https://doi.org/10.1007/s40264-015-0267-y
  12. Quenard F, Fournier P, Drancourt M, Brouqui P. Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis. International Journal Antimicrobial Agents. 2017;50(2):252-254.  https://doi.org/10.1016/j.ijantimicag.2017.01.042
  13. Lindberg A, Larsson LG, Muellerova H, Rönmark E, Lundbäck B. Up-to-date on mortality in COPD — report from the OLIN COPD study. BMC Pulmonary Medicine. 2012;12:1.  https://doi.org/10.1186/1471-2466-12-1
  14. Ezzati M, Lopez A. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362(9387):847-852.  https://doi.org/10.1016/S0140-6736(03)14338-3
  15. Fu Y, Kang N, Yu Y, Mi Y, Guo J, Wu J, Weng C. Polyphenols, flavonoids and inflammasomes: the role of cigarette smoke in COPD. European Respiratory Journal. 2022;31(164):220-228.  https://doi.org/10.1183/16000617.0028-2022
  16. Wessels J, Walsh C, Nel M. Smoking habits and alcohol use of patients with tuberculosis at Standerton Tuberculosis Specialised Hospital, Mpumalanga, South Africa. Health SA Gesondheid. 2019;8(24):1146. https://doi.org/10.4102/hsag.v24i0.1146
  17. Chan E, Keane J, Iseman M. Should cigarette smoke exposure be a criterion to treat latent tuberculous infection? American Journal of Respiratory Critical Care Medicine. 2010;182(8):990-992.  https://doi.org/10.1164/rccm.201006-0861ED
  18. Zhao J, Li M, Chen J, Wu X, Ning Q, Zhao J, Xu Y, Xie J, Yu J. Smoking status and gene susceptibility play important roles in the development of chronic obstructive pulmonary disease and lung function decline: A population-based prospective study. Medicine. 2017;96(25):72-83.  https://doi.org/10.1097/MD.0000000000007283
  19. Khosa C, Bhatt N, Massango I, Azam K, Saathoff E, Bakuli A, Riess F, Ivanova O, Hoelscher M, Rachow A. Development of chronic lung impairment in Mozambican TB patients and associated risks. BMC Pulmonary Medicine. 2020;20(1):127.  https://doi.org/10.1186/s12890-020-1167-1
  20. Gai X, Allwood B, Sun Y. Post-tuberculosis lung disease and chronic obstructive pulmonary disease. Chin Med J (Engl). 2023 Aug20;136(16):1923-1928. https://doi:10.1097/CM9.0000000000002771.Epub2023Jul14.PMID:37455331;PMCID:PMC10431356.
  21. Ivanova O, Hoffmann V, Lange C, Hoelscher M, Rachow A. Post-tuberculosis lung impairment: Systematic review and meta-analysis of spirometry data from 14621 people. European Respiratory Review. 2023;32(168):220-221.  https://doi.org/10.1183/16000617.0221-2022
  22. Wu C, Li G, Huang C, Cheng Y, Chen C, Chien J, Kuo P, Kuo L, Lai F. Acute Exacerbation of a Chronic Obstructive Pulmonary Disease Prediction System Using Wearable Device Data, Machine Learning, and Deep Learning: Development and Cohort Study. JMIR Mhealth Uhealth. 2021;9(5):e22591. https://doi.org/10.2196/22591
  23. Aghapour M, Ubags N, Bruder D, Hiemstra P, Sidhaye V, Rezaee F, Heijink I. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD. European Respiratory Review. 2022;31(163):210-212.  https://doi.org/10.1183/16000617.0112-2021
  24. Bam T, Aditama T, Chiang C, Rubaeah R, Suhaemi A. Smoking cessation and smokefree environments for tuberculosis patients in Indonesia — a cohort study. BMC Public Health. 2015;15:604.  https://doi.org/10.1186/s12889-015-1972-2
  25. Awaisu A, Nik Mohamed M, Mohamad Noordin N, Abd Aziz N, Syed Sulaiman S, Muttalif A. The SCIDOTS Project: evidence of benefits of an integrated tobacco cessation intervention in tuberculosis care on treatment outcomes. Substance Abuse Treatment, Prevention and Policy. 2011;6:26.  https://doi.org/10.1186/1747-597X-6-26
  26. Siddiquea B, Islam M, Bam T, Satyanarayana S, Enarson D, Reid A. High quit rate among smokers with tuberculosis in a modified smoking cessation programme in Dhaka, Bangladesh. Public Health Action. 2013;3(3):243-246.  https://doi.org/10.5588/pha.13.0051
  27. Chumovatov NV, Antonov NS, Sakharova GM, Chernyh NA, Romanov VV, Ergeshov AE. Analysis of the effectiveness of smoking cessation in patients with pulmonary tuberculosis in a hospital setting. Pul’monologiya. 2022;32(6):869-875. (In Russ.). https://doi.org/10.18093/0869-0189-2022-32-6-869-875

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.